Especially in the field of autoimmunity, understanding this crosstalk is of high relevance, as multiple treatments are relying on inhibiting one of the two systems specifically (e.g., Adalimumab or Upadacitinib for blocking either TNFα or primarily IFN-I signaling, respectively). This evidence concerns the gene TNF and Autoimmunity.